TIME COURSE OF CHANGES IN OPTIC DISK NEOVASCULARIZATION AFTER A SINGLE INTRAVITREAL BEVACIZUMAB INJECTION

Retina. 2019 Jun;39(6):1149-1153. doi: 10.1097/IAE.0000000000002107.

Abstract

Purpose: To evaluate the longitudinal changes in optic disk neovascularization (NVD) after intravitreal bevacizumab injection using optical coherence tomography angiography.

Methods: In this prospective, interventional, case series, eyes with NVD secondary to diabetic retinopathy were enrolled. En face optical coherence tomography angiographic images were obtained from the optic disks before and 3 hours, 6 hours, 24 hours, 7 days, and 30 days after intravitreal bevacizumab injection. The size and flow area of the neovascularization were measured by two graders.

Results: Eleven eyes of 9 patients with a mean age of 52.11 ± 9.48 years were included. The reduction in the NVD size and flow area was statistically significant at 24 hours, 7 days, and 30 days after injections compared with the baseline measurements (all P < 0.05). The decremental regression in the NVD size and flow area continued during the study course. The changes were not statistically significant in 3-hour and 6-hour measurements (all P > 0.05).

Conclusion: In this study, statistically significant regression in the NVD size and flow area was observed as early as 24 hours after a single intravitreal bevacizumab injection, with a continued decreasing trend for at least a 1-month period.

MeSH terms

  • Adult
  • Aged
  • Angiogenesis Inhibitors / administration & dosage
  • Bevacizumab / administration & dosage*
  • Dose-Response Relationship, Drug
  • Female
  • Fluorescein Angiography / methods*
  • Follow-Up Studies
  • Fundus Oculi
  • Humans
  • Intravitreal Injections
  • Male
  • Middle Aged
  • Neovascularization, Pathologic / diagnosis
  • Neovascularization, Pathologic / drug therapy
  • Optic Disk / blood supply*
  • Optic Nerve Diseases / diagnosis*
  • Optic Nerve Diseases / drug therapy
  • Prospective Studies
  • Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
  • Tomography, Optical Coherence / methods*
  • Treatment Outcome
  • Visual Acuity*

Substances

  • Angiogenesis Inhibitors
  • Bevacizumab
  • Receptors, Vascular Endothelial Growth Factor